SAN DIEGO, Dec. 3 /PRNewswire/ -- Biocept, Inc. (“Biocept”), an emerging leader in biotechnology, announced today their CLIA laboratory has been awarded accreditation by the Commission on Laboratory Accreditation of the College of American Pathologists (CAP), based on the results of a recent on-site inspection. The laboratory’s director, Philip D. Cotter, Ph.D., FACMG, was advised of this national recognition and congratulated for the “excellence of services being provided.”
About Biocept
Biocept, an emerging biotechnology leader in cell separation technology, is developing a new, powerful class of diagnostic assays for personalized medicine in early detection, diagnosis and monitoring of cancer. The CEE(TM) Cell Enrichment and Extraction platform combines sophisticated attachment chemistry with mathematically modeled fluid dynamics and nanotechnology to enable earlier, accurate, less invasive diagnoses. Isolation, purification and analysis of rare cells, such as circulating tumor cells, are managed within our state-of-the-art CLIA-accredited laboratory. The clinical laboratory is accredited by the College of American Pathologists (CAP) and holds licenses in California and several other states.
CONTACT: Jennifer K. Crittenden of Biocept, Inc., +1-858-320-8200, toll
free, 1-888-332-7729, info@biocept.com
Web site: http://www.biocept.com/
